Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL3582415

CCNCc1ccccc1.N

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.61
KMT2A Q03164 1/20 0.61
TDP1 Q9NUW8 1/20 0.61
MAOA P21397 1/20 0.54
MAPT P10636 2/20 0.52
KDM4E B2RXH2 1/20 0.52
CYP3A4 P08684 1/20 0.52
GAA P10253 3/20 0.52
CHRM2 P08172 1/20 0.52
PKM P14618 1/20 0.50
SIGMAR1 Q99720 1/20 0.48
ADH1B P00325 1/20 0.48
ADH1C P00326 1/20 0.48
ADH1A P07327 1/20 0.48
ADH7 P40394 1/20 0.48
IDO1 P14902 2/20 0.48
THRB P10828 1/20 0.48
TP53 P04637 1/20 0.48
ALPL P05186 1/20 0.47
HPGD P15428 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzene SCHEMBL7471176 0.97 MEN1 (0.64) MEN1KMT2ATDP1MAOAMAPT
SCHEMBL2146 0.97 MEN1 (0.64) MEN1KMT2ATDP1MAOAMAPT
Bromide SCHEMBL7087997 0.95 MEN1 (0.61) MEN1KMT2ATDP1MAOAMAPT
Water SCHEMBL1868146 0.95 MEN1 (0.61) MEN1KMT2ATDP1MAOAMAPT
SCHEMBL10813092 0.95 MEN1 (0.61) MEN1KMT2ATDP1MAOAMAPT
Hydrochloric Acid SCHEMBL1551607 0.95 MEN1 (0.61) MEN1KMT2ATDP1MAOAMAPT
Lithium SCHEMBL31374748 0.95 MEN1 (0.61) MEN1KMT2ATDP1MAOAMAPT
Iodide SCHEMBL17241299 0.95 MEN1 (0.61) MEN1KMT2ATDP1MAOAMAPT
SCHEMBL21065761 0.95 MEN1 (0.61) MEN1KMT2ATDP1MAOAMAPT
Ethyne SCHEMBL4550660 0.93 MEN1 (0.58) MEN1KMT2ATDP1MAOAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102702007-A Synthesis of 5-methoxyl-2-methylene-Nmethylformamide indene compounds SHENGSHI TAIKE BIOMEDICAL TECHNOLOGY SUZHOU CO LTD 2012-10-03 CN claimed
CN-102702007-A Synthesis of 5-methoxyl-2-methylene-Nmethylformamide indene compounds SHENGSHI TAIKE BIOMEDICAL TECHNOLOGY SUZHOU CO LTD 2012-10-03 CN disclosed
US-20100048543-A1 PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY ASTRAZENECA AB (SE) 2010-02-25 US disclosed
EP-1863805-A1 PYRIMIDINE COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY AstraZeneca AB (SE) 2007-12-12 EP disclosed
WO-2006082373-A1 PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY ASTRAZENECA AB (SE) 2006-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048543-A1 PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY TEK, TYMP, TIE1 MEN1 2463/4885KMT2A 815/4885TDP1 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.